Literature DB >> 21464733

Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.

Yoon Hee Lee1, Jin-hyung Heo, Tae Heon Kim, Haeyoun Kang, Gwangil Kim, Jiyoung Kim, Sang-ho Cho, Hee Jung An.   

Abstract

The principal objective of this study was to comprehensively assess the clinicopathologic and prognostic impacts of the expression of various cell cycle regulatory proteins in patients with ovarian epithelial tumors. The tissue microarrays were constructed from formalin-fixed, paraffin-embedded tissues of 205 ovarian epithelial tumors. We investigated 55 benign (20 serous cystadenomas, 17 mucinous cystadenomas, and 18 endometriotic cysts), 72 borderline (26 serous borderline tumors and 46 mucinous borderline tumors), and 78 malignant tumors (45 serous carcinomas, 10 mucinous adenocarcinomas, 15 endometrioid adenocarcinomas, and 8 clear cell carcinomas). Immunohistochemical staining was performed using antibodies to p16(Ink4a), p53, p21(Waf1/Cip1), p27(Kip1), Cyclin D1, Cyclin E, Cyclin A, Cyclin B1, and Cyclin-dependent Kinase2. We noted significantly different levels of p53 and Cyclin B1 expressions between malignant and borderline tumors and between borderline and benign tumors excepting the mucinous type. The p21(Waf1/Cip1) and Cyclin A were significantly overexpressed in malignant tumors compared with borderline tumors. Cyclin A, Cyclin E, and p16(Ink4a) were more pronounced proteins, showing differential expression patterns among the histologic types of ovarian carcinomas. We determined that the overexpression of p16(Ink4a) (P=0.031), Cyclin E (P=0.009), and Cyclin-dependent Kinase2 (P=0.004) were significantly associated with higher tumor grades. Overexpression of p16(Ink4a) was correlated with both lymph node metastasis (P=0.030) and distant metastasis (P=0.034). Overexpression of Cyclin E was associated with advanced stage (P=0.004). Higher tumor grade (P=0.008), advanced stage (P=0.001), mucinous histologic type (P=0.012), low expression levels of p16(Ink4a) (P=0.032), and overexpression of p53 (P=0.032) were associated with poor overall survival on multivariate analysis in patients with ovarian cancer. In serous carcinomas, old age (P=0.005), distant metastasis (P=0.020), low expression of p16(Ink4a) (P=0.047), and overexpression of cytoplasmic p27(Kip1) (P=0.007) and Cyclin A (P=0.031) were all independent predictors of worse overall survival. Our data indicate that the overexpression of p16 and Cyclin E are valuable factors predicting disease progression and metastatic potential. Low p16(Ink4a) expression, overexpression of p53, cytoplasmic p27(Kip1), and Cyclin A are predictive markers for shorter overall survival in ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464733     DOI: 10.1097/PGP.0b013e3182063e71

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  15 in total

1.  Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis.

Authors:  Ying Wang; Kathy Qi Cai; Elizabeth R Smith; Toni M Yeasky; Robert Moore; Parvin Ganjei-Azar; Andres J Klein-Szanto; Andrew K Godwin; Thomas C Hamilton; Xiang-Xi Xu
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

Review 2.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

Review 3.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

4.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

5.  Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma.

Authors:  Ingiridur Skirnisdottir; Tomas Seidal; Helena Åkerud
Journal:  Int J Gynecol Cancer       Date:  2015-09       Impact factor: 3.437

6.  Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.

Authors:  Ashley S Felix; Mark E Sherman; Stephen M Hewitt; Munira Z Gunja; Hannah P Yang; Renata L Cora; Vicky Boudreau; Kris Ylaya; Jolanta Lissowska; Louise A Brinton; Nicolas Wentzensen
Journal:  Front Oncol       Date:  2015-02-09       Impact factor: 6.244

7.  Methylation of tumor suppressor genes in ovarian cancer.

Authors:  Filiz Ozdemir; Julide Altinisik; Ates Karateke; Hakan Coksuer; Nur Buyru
Journal:  Exp Ther Med       Date:  2012-09-18       Impact factor: 2.447

8.  Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor.

Authors:  Hongcheng Lv; Yang Shi; Li Zhang; Dan Zhang; Guang Liu; Zhengduo Yang; Yan Li; Fei Fei; Shiwu Zhang
Journal:  BMC Cancer       Date:  2014-08-08       Impact factor: 4.430

9.  Napsin A as a marker of clear cell ovarian carcinoma.

Authors:  Ingiridur Skirnisdottir; Kathrine Bjersand; Helena Akerud; Tomas Seidal
Journal:  BMC Cancer       Date:  2013-11-05       Impact factor: 4.430

10.  Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.

Authors:  Mayumi Kobayashi Kato; Hiroshi Yoshida; Yasuhito Tanase; Masaya Uno; Mitsuya Ishikawa; Tomoyasu Kato
Journal:  Pathol Oncol Res       Date:  2021-03-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.